Ventilated · patients with acute organophosphate pesticide poisoning
It is very uncertain whether higher dose changes ventilated compared with lower dose (very low certainty).
1 finding from 1 review
RIFLE (Risk or worse) · patients with Intravascular Volume Depletion
High MW HES showed no clear difference in RIFLE (Risk or worse) compared with low MW HES (moderate certainty).
1 finding from 1 review
RIFLE (Injury or worse) · patients with Intravascular Volume Depletion
High MW HES showed no clear difference in RIFLE (Injury or worse) compared with low MW HES (moderate certainty).
1 finding from 1 review
RIFLE (Failure) · patients with Intravascular Volume Depletion
1 finding from 1 review
Frequency of defecation (mean number of bowel movements per week) · patients aged 0 to 18 years with a diagnosis of functional constipation
1 finding from 1 review
Need for extra treatment · patients aged 0 to 18 years with a diagnosis of functional constipation
It is very uncertain whether high dose PEG changes need for additional therapy compared with low dose PEG (very low certainty).
1 finding from 1 review
Faecal incontinence · patients aged 0 to 18 years with a diagnosis of functional constipation
It is very uncertain whether high dose PEG changes faecal incontinence compared with low dose PEG (very low certainty).
1 finding from 1 review
Adverse events · patients aged 0 to 18 years with a diagnosis of functional constipation
It is very uncertain whether high dose PEG changes adverse events compared with low dose PEG (very low certainty).
1 finding from 1 review
Pain during activity (short‐term) · patients with patellofemoral pain syndrome (untreated PFPS of over 2 months in duration)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · patients with patellofemoral pain syndrome (untreated PFPS of over 2 months in duration)
It is very uncertain whether high‐intensity changes usual pain (short‐term) VAS (0 to 10; higher scores mean worse pain) compared with low‐intensity exercise programmes (very low certainty).
2 findings from 1 review
Pain during activity (long‐term) VAS (0 to 10; higher scores mean worse pain) · patients with patellofemoral pain syndrome (untreated PFPS of over 2 months in duration)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Functional ability · patients with patellofemoral pain syndrome (untreated PFPS of over 2 months in duration)
It is very uncertain whether high‐intensity changes functional ability (short‐term) FIQ modified (0 to 16; higher scores… compared with low‐intensity exercise programmes (very low certainty).
2 findings from 1 review
Recovery (long‐term) · patients with patellofemoral pain syndrome (untreated PFPS of over 2 months in duration)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical relapse · people with surgically‐induced remission in Crohn's disease
High dose 5‐ASA showed no clear difference in clinical relapse compared with low dose 5‐ASA (moderate certainty).
1 finding from 1 review
Endoscopic recurrence · people with surgically‐induced remission in Crohn's disease
High dose 5‐ASA showed no clear difference in endoscopic recurrence compared with low dose 5‐ASA (moderate certainty).
1 finding from 1 review
Radiologic relapse · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people with surgically‐induced remission in Crohn's disease
High dose 5‐ASA showed no clear difference in adverse events compared with low dose 5‐ASA (low certainty).
1 finding from 1 review
Serious adverse events · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · people with surgically‐induced remission in Crohn's disease
High dose 5‐ASA showed no clear difference in withdrawal due to adverse events compared with low dose 5‐ASA (low certainty).
1 finding from 1 review
Health related quality of life · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found